Search for: "CIPLA"
Results 101 - 120
of 202
Sort by Relevance
|
Sort by Date
27 Apr 2010, 10:58 pm
Solstice International Partners et al (Docket Report) US: FTC annual report highlights the Commission’s patent settlement efforts (FDA Law Blog) Products Adcirca (Tadalafil) – US: Declaratory judgement of non-infringement and invalidity based on ANDA to manufacture generic Adcirca: Synthon v Eli Lilly et al (Patent Docs) Amrix (Cyclobenzaprine) – US: Mylan seeks declaratory judgment of noninfringement, unenforceability and invalidity of Amrix patent, based on Mylan’s… [read post]
23 Apr 2010, 9:57 am
The Ecuador CL is a tiered royalty bearing license.Scanned documents pertaining to Cipla's CL are available, here. [read post]
22 Apr 2010, 3:51 am
Teva (Orange Book Blog) (FDA Law Blog) Levistra (Vardenafil) – US: District Court Delaware: Patent infringement complaint following ANDA filing: Bayer Schering Pharma AG et al v Teva Pharmaceuticals USA, Inc et al (Patent Docs) Nexavar (Sorafenib) – India: Bayer sues Cipla for infringement of Nexavar patent before Delhi High Court (Spicy IP) Norfloxacin – Canada: Federal Court: Judgment in s 8 proceeding: Apotex v Merck (Pharmacapsules) Prandin (Repaglinide) – US:… [read post]
18 Apr 2010, 6:22 am
Cipla patent infringement case.The patent in question is IN215758 coming from Indian application IN/PCT/2001/00799/MUM.Friends in Delhi have given this update:i) A counterclaim was filed in Court only yesterday and it was not on record;ii) A formal written statement to the above counter claim is now to be filed [read post]
3 Apr 2010, 7:44 am
Lately Cipla sold its money-spinning contraceptive brand product “i-pill” to Piramal Healthcare for INR. 95 crores. [read post]
1 Apr 2010, 3:04 am
., LLC et al v Heritage Pharmaceuticals Inc (Patent Docs) Gemzar (Gemcitabine) – US: Eli Lilly files patent infringement suit in S D Indiana against Hospira following Para IV challenge (Patent Docs) Nexavar (Sorafenib) – India: Bayer sues Cipla for patent infringement on Sorafenib (Generic Pharmaceuticals) Viagra (Sildenafil) – Brazil: Patent protection in Brazil: is this the end for Viagra? [read post]
24 Mar 2010, 11:20 pm
Bayer and Cipla are fighting a pitched battle on the aspect of linkage of patents with drug approval [regulatory approval] in context of Sorafenib Tosylate [anti cancer drug- Nexavar (R)]. [read post]
18 Mar 2010, 2:30 am
Cipla Ltd & Others (Spicy IP) Indian civil society raises concerns over US industry-sponsored IP summits (IP Watch) India: Making Patents Work – Feroz Ali (Spicy IP) India: AIDS patients protest EU-India trade agreement (IP Watch) India: Trade secrets and biotechnology – Lecture V notes (SiNApSE) Mexico: Mexican Supreme Court confirms linkage is available for all product patents, including formulation patents (Olivares & CIA) Poland: No hidden advertising of… [read post]
24 Feb 2010, 2:11 am
(Patent Docs) US: PhRMA representative questions follow-on biologics paper (Patent Docs) USPTO announces agenda for next biotechnology/chemical/pharmaceutical customer partnership meeting (Patent Docs) Products Arzerra (Ofatumumab) – US: Glaxo Group, GlaxoSmithKline seek declaratory judgment of invalidity and non-infringement against Genentech, City of Hope (Patent Docs) Cipro (Ciprofloxacin) – US: Bayer files patent infringement complaints against Lupin in Maryland and Delaware… [read post]
24 Feb 2010, 2:11 am
(Patent Docs) US: PhRMA representative questions follow-on biologics paper (Patent Docs) USPTO announces agenda for next biotechnology/chemical/pharmaceutical customer partnership meeting (Patent Docs) Products Arzerra (Ofatumumab) – US: Glaxo Group, GlaxoSmithKline seek declaratory judgment of invalidity and non-infringement against Genentech, City of Hope (Patent Docs) Cipro (Ciprofloxacin) – US: Bayer files patent infringement complaints against Lupin in Maryland and Delaware… [read post]
17 Feb 2010, 5:10 am
(IP Whiteboard) EU: European Commission probes for evidence of foul play among pharmaceutical companies (IP Whiteboard) EU / UK: Of conflict and cooperation: when national courts and the EPO differ: Eli Lilly and Company v Human Genome Sciences (PatLit) India: Drug makers decry Indian patent law (GenericsWeb) India: India-EU gets flak in India (GenericsWeb) India: Delhi High Court: Rejection of application based on pre-grant representation may be appealed to IPAB: UCB Farchim SA v Cipla… [read post]
12 Feb 2010, 6:55 am
“The U.S. would grant a patent to a piece of toilet paper,” says Amar Lulla, chief executive of Cipla, the Indian generics drugmaker. [read post]
10 Feb 2010, 4:47 pm
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://duncanbucknell.com/subscribe/ Highlights this week included: India: Rejections from pre-grant appealable to IPAB by patent applicant: UCB Farchim SA v Cipla & Ors (Generic Pharmaceuticals and IP) (The Vanishing Point) (Indian Patent Oppositions) (Spicy IP) (Spicy IP) India: Nay patent linkages: Bayer v UOI upheld by Division Bench of Delhi High Court (Spicy IP) (Generic… [read post]
8 Feb 2010, 12:52 pm
Manish Rajan of livemint.com reported that the Delhi High Court on Monday dismissed the petition filed by Global Biopharma major UCB Frachim against the Indian generic major Cipla and the Indian Patent Office over rejection of its patent for a new anti-allergic drug. [read post]
21 Jan 2010, 1:00 am
UCB moves to the Delhi High Court against Cipla & IPO (Patentcircle) Argentina: custom confiscates counterfeit medicines (IP tango) India: Beejasurs of the Indian seed market (Spicy IP) IP Border measures concerning goods allegedly infringing Intellectual Property rights – article (IP tango) Wisconsin Alumni Research Foundation (WARF) wins appeal in patent battle with Xenon (Technology Transfer Tactics), (IP Licensing Law) President Obama reportedly seeks to shorten… [read post]
19 Jan 2010, 2:14 pm
Press Trust of India (PTI) reported that Global Biopharma major UCB Farchim yesterday approached the Delhi High Court against the Indian generic manufacturer Cipla and the Indian Patent office over rejection of its patent for a new anti-allergic drug. [read post]
9 Dec 2009, 3:59 pm
: Roche v Cipla (Spicy IP) India, intellectual property and biotechnology industry – to protect, or not to protect (Biotech Blog) Italy: SPCs, competition and refusal to supply – Italian Competition Authority’s responses to ‘refusal to deal’ questionnaire (The SPC Blog) US: Ariad v Lilly – amicus briefs by Regents of University of California et al and various companies (Patent Docs) (Patent Docs) US: Ariad v Lilly – A look back at the roots of the… [read post]
25 Nov 2009, 12:00 pm
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://duncanbucknell.com/subscribe/ Highlights this week included: Ecuador to define its compulsory licence legislation (IP Watch) (Patently-O) Tavanic (Levofloxacin) – UK: Supreme Court refuses permission to appeal in Generics (UK) Ltd v Daiichi Pharmaceuticals (The SPC Blog) (JIPLP) General Nil: The value of patents in a major crisis such as an influenza pandemic – Paper by… [read post]
25 Nov 2009, 3:00 am
(Patents4Life) R&D: the biggest spenders – discussion of 2009 EU Industrial R&D Scoreboard (IPKat) New search tool by OHIM and participating offices (Class 46) EPO – Many more changes coming next year (IPKat) EU-South Korea Free Trade Agreement: For the first time in a bilateral agreement between EU and a third country, the EU provides for the protection of European geographical indications (Class 46) Three more PGI regulations in force: Limone Interdonato Messina, Proscuitto di… [read post]
25 Sep 2009, 5:03 am
Consider Cipla's drug "Valcept", which is a generic version of Roche's patented anti-infective "Valcyte". [read post]
